Description

GHRP‑6 (Growth Hormone‑Releasing Peptide‑2)

• GHRP‑6 is a synthetic hexapeptide that acts as a potent growth hormone secretagogue by stimulating the ghrelin (GHS‑R) receptor to promote endogenous growth hormone (GH) release.
• Investigational agent used in research and selected clinical contexts to study GH axis physiology, body composition, and recovery.

Key benefits (research findings)

• Stimulates pulsatile release of endogenous GH, potentially improving anabolic and recovery signaling.
• Can support increases in lean body mass and recovery in experimental models when combined with appropriate nutrition and exercise.
• Useful for probing GH axis function and as a research tool for endocrine and metabolic studies.
• May produce stronger GH responses than some secretagogues; effects on ACTH/cortisol can vary.

Primary uses

• Research into GH physiology, aging, sarcopenia, cachexia, metabolic regulation, and recovery.
• Diagnostic/provocative testing of pituitary GH reserve in specialized clinical and research settings.
• Preclinical and clinical trials examining therapeutic potential for catabolic states under regulatory oversight.

Suggested use (research/clinical context)

• Administered by subcutaneous or intramuscular injection per protocol; dosing, timing (often timed to exploit nocturnal GH pulses), and frequency depend on study objectives.
• Often employed in single‑dose provocative tests or short‑course stimulation regimens; combine with appropriate endocrine monitoring.
• Establish dose‑finding and safety monitoring in pilot studies before broader application.

Safety and storage

• Safety profile: investigational. Reported adverse effects include transient injection‑site discomfort, water retention, paresthesia, increased appetite, and possible mild elevations in cortisol or prolactin. Monitor glucose tolerance as GH can affect insulin sensitivity.
• Contraindications/precautions: avoid in active malignancy, uncontrolled diabetes, pregnant or breastfeeding individuals, or where GH stimulation is unsafe. Assess personal/family medical history and consult supervising clinicians.
• Handling: use aseptic technique and PPE when preparing/administering. Follow institutional biosafety and waste‑disposal procedures.
• Storage: store lyophilized peptide per supplier instructions (typically refrigerated or frozen for long‑term storage). Reconstitute with sterile diluent, aliquot into single‑use volumes when appropriate, minimize freeze–thaw cycles, and protect from light and moisture. Discard reconstituted solutions per vendor stability guidance.

Quick facts

• Mechanism: ghrelin receptor (GHS‑R) agonist → stimulates endogenous GH release.
• Status: investigational for many therapeutic uses; clinical application should occur only within approved protocols and under medical supervision.
• Procurement: available to research institutions and clinics from legitimate suppliers with appropriate approvals.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.